| dc.contributor.author | Goldman, Aaron | |
| dc.contributor.author | Majumder, Biswanath | |
| dc.contributor.author | Dhawan, Andrew | |
| dc.contributor.author | Ravi, Sudharshan | |
| dc.contributor.author | Goldman, David | |
| dc.contributor.author | Kohandel, Mohammad | |
| dc.contributor.author | Majumder, Pradip K. | |
| dc.contributor.author | Sengupta, Shiladitya | |
| dc.date.accessioned | 2015-04-30T13:52:01Z | |
| dc.date.available | 2015-04-30T13:52:01Z | |
| dc.date.issued | 2015-02 | |
| dc.date.submitted | 2014-07 | |
| dc.identifier.issn | 2041-1723 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/96854 | |
| dc.description.abstract | Understanding the emerging models of adaptive resistance is key to overcoming cancer chemotherapy failure. Using human breast cancer explants, in vitro cell lines, mouse in vivo studies and mathematical modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44[superscript Hi]CD24[superscript Hi] chemotherapy-tolerant state. This state is associated with a clustering of CD44 and CD24 in membrane lipid rafts, leading to the activation of Src Family Kinase (SFK)/hemopoietic cell kinase (Hck) and suppression of apoptosis. The use of pharmacological inhibitors of SFK/Hck in combination with taxanes in a temporally constrained manner, where the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly sensitizes the chemotolerant cells to the chemotherapy. This approach of harnessing chemotherapy-induced phenotypic cell state transition for improving antitumour outcome could emerge as a translational strategy for the management of cancer. | en_US |
| dc.description.sponsorship | United States. Dept. of Defense (Breast Cancer Research Program (U.S.) Collaborative Innovator Grant W81XWH-09-1-0700) | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) (RO1 1R01CA135242) | en_US |
| dc.description.sponsorship | United States. Dept. of Defense (Breakthrough Award BC132168) | en_US |
| dc.description.sponsorship | American Lung Association (Innovation Award LCD-259932-N) | en_US |
| dc.description.sponsorship | Indo-US Science and Technology Forum (Indo-US Joint Center Grant) | en_US |
| dc.description.sponsorship | American Cancer Society (Postdoctoral Fellowship 122854-PF-12-226-01-CDD) | en_US |
| dc.language.iso | en_US | |
| dc.publisher | Nature Publishing Group | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1038/ncomms7139 | en_US |
| dc.rights | Creative Commons Attribution | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
| dc.source | Nature Publishing Group | en_US |
| dc.title | Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Goldman, Aaron, Biswanath Majumder, Andrew Dhawan, Sudharshan Ravi, David Goldman, Mohammad Kohandel, Pradip K. Majumder, and Shiladitya Sengupta. “Temporally Sequenced Anticancer Drugs Overcome Adaptive Resistance by Targeting a Vulnerable Chemotherapy-Induced Phenotypic Transition.” Nature Communications 6 (February 11, 2015): 6139. | en_US |
| dc.contributor.department | Harvard University--MIT Division of Health Sciences and Technology | en_US |
| dc.contributor.mitauthor | Goldman, Aaron | en_US |
| dc.contributor.mitauthor | Sengupta, Shiladitya | en_US |
| dc.relation.journal | Nature Communications | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dspace.orderedauthors | Goldman, Aaron; Majumder, Biswanath; Dhawan, Andrew; Ravi, Sudharshan; Goldman, David; Kohandel, Mohammad; Majumder, Pradip K.; Sengupta, Shiladitya | en_US |
| mit.license | PUBLISHER_CC | en_US |
| mit.metadata.status | Complete | |